The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Candel Therapeutics Inc’s stock clocked out at $5.5, down -4.18% from its previous closing price of $5.74. In other words, the price has decreased by -$4.18 from its previous closing price. On the day, 0.77 million shares were traded. CADL stock price reached its highest trading level at $5.98 during the session, while it also had its lowest trading level at $5.48.
Ratios:
To gain a deeper understanding of CADL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.25 and its Current Ratio is at 8.25. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On September 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 301940672 and an Enterprise Value of 222184672.
Stock Price History:
The Beta on a monthly basis for CADL is -0.94, which has changed by -0.4236948 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $13.68, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is 3.96%, while the 200-Day Moving Average is calculated to be -2.83%.
Shares Statistics:
It appears that CADL traded 850.27K shares on average per day over the past three months and 1306710 shares per day over the past ten days. A total of 54.90M shares are outstanding, with a floating share count of 41.06M. Insiders hold about 25.21% of the company’s shares, while institutions hold 36.98% stake in the company. Shares short for CADL as of 1764288000 were 8272637 with a Short Ratio of 9.73, compared to 1761868800 on 7479907. Therefore, it implies a Short% of Shares Outstanding of 8272637 and a Short% of Float of 19.03.
Earnings Estimates
. The current rating of Candel Therapeutics Inc (CADL) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.41 and -$0.8 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
